

## CXCR4 antibody - N-terminal region

Rabbit Polyclonal Antibody Catalog # AI10012

## **Product Information**

**Application** WB, IHC, FC **Primary Accession** P61073

Other Accession P61073, NP 003458, NM 003467
Reactivity Human, Mouse, Rat, Rabbit, Pig, Horse

Predicted Human, Rabbit

Host Rabbit
Clonality Polyclonal
Calculated MW 39746

## **Additional Information**

**Gene ID** 7852

Alias Symbol CD184, D2S201E, FB22, HM89, HSY3RR, LAP3, LCR1, LESTR, NPY3R, NPYR,

NPYRL, NPYY3R, WHIM

Other Names C-X-C chemokine receptor type 4, CXC-R4, CXCR-4, FB22, Fusin, HM89, LCR1,

Leukocyte-derived seven transmembrane domain receptor, LESTR, Lipopolysaccharide-associated protein 3, LAP-3, LPS-associated protein 3, NPYRL, Stromal cell-derived factor 1 receptor, SDF-1 receptor, CD184, CXCR4

**Target/Specificity** CXCR4 is a CXC chemokine receptor specific for stromal cell-derived factor-1.

The protein has 7 transmembrane regions and is located on the cell surface. It acts with the CD4 protein to support HIV entry into cells and is also highly expressed in breast cancer cells. Mutations in this gene have been associated with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. This gene encodes a CXC chemokine receptor specific for stromal cell-derived factor-1. The protein has 7

transmembrane regions and is located on the cell surface. It acts with the CD4 protein to support HIV entry into cells and is also highly expressed in breast cancer cells. Mutations in this gene have been associated with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. Alternate

transcriptional splice variants, encoding different isoforms, have been

characterized.

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium

azide and 2% sucrose.

**Reconstitution & Storage** Add 50 ul of distilled water. Final anti-CXCR4 antibody concentration is 1

mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at

-20°C. Avoid repeat freeze-thaw cycles.

**Precautions** CXCR4 antibody - N-terminal region is for research use only and not for use in

## **Protein Information**

CXCR4 Name

**Function** Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by

increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation (PubMed:10452968, PubMed:18799424, PubMed:24912431,

PubMed: 28978524). Involved in the AKT signaling cascade

(PubMed: 24912431). Plays a role in regulation of cell migration, e.g. during wound healing (PubMed: 28978524). Acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels (PubMed: 20228059). Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed: 11276205). Involved in hematopoiesis and in cardiac ventricular septum formation. Also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Involved in cerebellar

development. In the CNS, could mediate hippocampal-neuron survival (By

similarity).

**Cellular Location** Cell membrane; Multi-pass membrane protein. Cell junction. Early endosome.

> Late endosome. Lysosome. Note=In unstimulated cells, diffuse pattern on plasma membrane. On agonist stimulation, colocalizes with ITCH at the plasma membrane where it becomes ubiquitinated. In the presence of antigen, distributes to the immunological synapse forming at the T- cell-APC contact area, where it localizes at the peripheral and distal supramolecular

activation cluster (SMAC)

**Tissue Location** Expressed in numerous tissues, such as peripheral blood leukocytes, spleen,

thymus, spinal cord, heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, cerebellum, cerebral cortex and medulla (in microglia as well as in astrocytes), brain microvascular, coronary artery and umbilical cord

endothelial cells Isoform 1 is predominant in all tissues tested


**Background** 


This is a rabbit polyclonal antibody against CXCR4. It was validated on Western Blot using a cell lysate as a positive control. Abgent strives to provide antibodies covering each member of a whole protein family of your interest. We also use our best efforts to provide you antibodies recognize various epitopes of a target protein. For availability of antibody needed for your experiment, please inquire (sales@abgent.com).

**Images** 


CXCR4 antibody - N-terminal region (AI10012) in Human HMEC-1, A549 cells using Flow Cytometry

Sample Type: HMEC-1 and A549 cells







CXCR4 antibody - N-terminal region (AI10012) in Human 721\_B cells using Western Blot CXCR4 antibody - N-terminal region (AI10012) validated by WB using 721\_B cell lysate at 0.2-1  $\mu$ g/ml.



CXCR4 antibody - N-terminal region (AI10012) in Human endothelial cells using Western Blot CXCR4 antibody - N-terminal region (AI10012) validated by WB using human microvascular endothelial cells (25ug) at 1:1000.



CXCR4 antibody - N-terminal region (AI10012) in Human HMEC-1, A549 cells using Immunohistochemistry Immunohistochemistry with HMEC-1 and A549 cells tissue



CXCR4 antibody - N-terminal region (AI10012) in Human HMEC-1, A549 cells using Immunohistochemistry Sample Type: human colon tissues infected ex-vivo with

HIV-1

Green: Primary Blue: DAPI

Primary Dilution: 1:100


Secondary Antibody: Donkey anti-Rabbit AF 488


Secondary Dilution: 1:500

Image

Submitted by: Chiara Foglieni

San Raffaele Scientific Institute, Milan, Italy





CXCR4 antibody - N-terminal region (AI10012) in Human 721\_B cells using Western Blot WB Suggested Anti-CXCR4 Antibody Titration: 0.2-1 µg/ml

ELISA Titer: 1:312500

Positive Control: 721\_B cell lysate

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.